Journal of Cellular Physiology · 2009 · 67 citations · 31 references
MedicineMolecular BiologyPharmacologyBone MetabolismCell SignalingInflammationInflammatory SignalingMultiple MyelomaOsteoclast BiologyNf-κb SignalingNuclear Translocation Of Transcription FactorsProteasome InhibitorsRank SignalingRankl-mediated OsteoclastogenesisRefractory Multiple MyelomaRelapsed Multiple MyelomaSubcellular Targeting
Proteasome inhibitors represent a promising therapy for the treatment of relapsed and/or refractory multiple myeloma, a disease that is concomitant with osteolysis and enhanced osteoclast formation. While blockade of the proteosome pathway has been recently shown to influence osteoclast formation and function, the precise molecular cascade underlying these effects is presently unclear. Here, we provide evidence that proteasome inhibitors directly impair osteoclast formation and function via the disruption of key RANK-mediated signaling cascades. Disruption of the proteosome pathway using selective inhibitors (MG-132, MG-115, and epoxomicin) resulted in the accumulation of p62 and CYLD, and altered the subcellular targeting and distribution of p62 and TRAF6 in osteoclast-like cells. Proteosome inhibition also blocked RANKL-induced NF-kappaB activation, IkappaBalpha degradation and nuclear translocation of p65. The disruption in RANK-signaling correlated dose-dependently with an impairment in osteoclastogenesis, with relative potency epoxomicin > MG-132 > MG-115 based on equimolar concentrations. In addition, these inhibitors were found to impact osteoclastic microtubule organization and attenuate bone resorption. Based on these data we propose that deregulation of key RANK-mediated signaling cascades (p62, TRAF6, CYLD, and IkappaBalpha) underscores proteasome-mediated inhibition of osteolytic bone conditions.
31
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
David L. Lacey, Emma Timms, Hong‐Lin Tan et al. · Cell · 1998 · 5.5K citations · Full text
Hailing Hsu, David L. Lacey, Colin R. Dunstan et al. · Proceedings of the National Academy of Sciences · 1999 · 1.6K citations
TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling
Mark Lomaga, Wen‐Chen Yeh, Ildiko Sarosi et al. · Genes & Development · 1999 · 1.3K citations · Full text
Osteopetrosis in mice lacking NF-κB1 and NF-κB2
Violetta Iotsova, Jorge Caamaño, James Loy et al. · Nature Medicine · 1997 · 995 citations
Requirement for NF-κB in osteoclast and B-cell development
Guido Franzoso, Louise Carlson, Lianping Xing et al. · Genes & Development · 1997 · 994 citations · Full text